{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T00:06:10Z","timestamp":1759017970451,"version":"3.44.0"},"reference-count":11,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T00:00:00Z","timestamp":1607472000000},"content-version":"am","delay-in-days":374,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.annder.2019.08.014","type":"journal-article","created":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T08:01:48Z","timestamp":1571644908000},"page":"817-820","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["M\u00e9ningococc\u00e9mie subaigu\u00eb sous adalimumab"],"prefix":"10.1016","volume":"146","author":[{"given":"N.","family":"Salinas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Etienne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.-M.","family":"Roguedas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Le Flahec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Misery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2019.08.014_bib0070","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.revmed.2009.11.010","article-title":"Fi\u00e8vre prolong\u00e9e associ\u00e9e \u00e0 une \u00e9ruption cutan\u00e9e diffuse r\u00e9v\u00e9lant une m\u00e9ningococc\u00e9mie chronique","volume":"31","author":"Roux","year":"2010","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.annder.2019.08.014_bib0075","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0151-9638(05)79282-6","article-title":"M\u00e9ningococc\u00e9mie chronique","volume":"132","author":"Carr\u00e9","year":"2005","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.annder.2019.08.014_bib0080","doi-asserted-by":"crossref","first-page":"R24","DOI":"10.1186\/ar4452","article-title":"Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5\u00a0years of therapy in a phase 3b and subsequent postmarketing observational study","volume":"16","author":"Burmester","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.annder.2019.08.014_bib0085","first-page":"1040","article-title":"Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy","volume":"34","author":"Genovese","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.annder.2019.08.014_bib0090","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1007\/s10067-014-2498-1","article-title":"Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2\u00a0to 4\u00a0years","volume":"33","author":"Kingsbury","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.annder.2019.08.014_bib0095","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1365-4632.2004.02571.x","article-title":"Infectious complications of tumor necrosis factor-alpha antagonists","volume":"44","author":"Bakleh","year":"2005","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.annder.2019.08.014_bib0100","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1517\/14740338.2015.1009036","article-title":"Infection risk associated with anti-TNF-\u03b1 agents: a review","volume":"14","author":"Murdaca","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.annder.2019.08.014_bib0105","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/MIB.0000000000001049","article-title":"Risk for Overall Infection with Anti-TNF and Anti-integrin Agents Used in IBD: A Systematic Review and Meta-analysis","volume":"23","author":"Shah","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.annder.2019.08.014_bib0110","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/apt.14420","article-title":"Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis","volume":"47","author":"Colombel","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.annder.2019.08.014_bib0115","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/path.4187","article-title":"Tumour necrosis factor in infectious disease","volume":"230","author":"Waters","year":"2013","journal-title":"J Pathol"},{"key":"10.1016\/j.annder.2019.08.014_bib0120","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.arcped.2016.03.011","article-title":"A propos de deux cas de m\u00e9ningococc\u00e9mie","volume":"23","author":"Thimmesch","year":"2016","journal-title":"Arch Pediatr"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963819303114?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963819303114?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:08:01Z","timestamp":1758971281000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963819303114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":11,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S0151963819303114"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2019.08.014","relation":{},"ISSN":["0151-9638"],"issn-type":[{"type":"print","value":"0151-9638"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"M\u00e9ningococc\u00e9mie subaigu\u00eb sous adalimumab","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2019.08.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}